Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study

Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study

Qianwen Ma,1,2,* Yu Chang,1,2,* Ling Li,1,2 Xin Li,1,2 Xinhua Wang,1,2 Jingjing Wu,1,2 Xiaorui Fu,1,2 Zhenchang Sun,1,2 Hui Yu,1,2 Xudong Zhang,1,2 Zhiyuan Zhou,1,2 Feifei Nan,1,2 Zhaoming Li,1,2 Xiyang Liu,1,2 Qian Zhao,1,2 Yang Li,1,2 Lan Zhang,2,3 Mingzhi Zhang,1,2 Lei Zhang1,2 1Department of Onc...

Full description

Bibliographic Details
Main Authors: Ma Q, Chang Y, Li L, Li X, Wang X, Wu J, Fu X, Sun Z, Yu H, Zhang X, Zhou Z, Nan F, Li Z, Liu X, Zhao Q, Li Y, Zhang L, Zhang M
Format: Article
Language:English
Published: Dove Medical Press 2019-02-01
Series:Cancer Management and Research
Subjects:
R-DA-EPOCH
R-CHOP
DHL
double CNG
efficacy and prognosis
Online Access:https://www.dovepress.com/efficacy-of-dose-adjusted-epoch-plus-rituximabr-chop-regimens-and-the--peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/efficacy-of-dose-adjusted-epoch-plus-rituximabr-chop-regimens-and-the--peer-reviewed-article-CMAR

Similar Items